leisure time
Previous article:
At least 13 dead in Texas as scorching temps continue
Next article: Despite FDA approval for Lyfgenia, Bluebird faces stiff competition
Next article: Despite FDA approval for Lyfgenia, Bluebird faces stiff competition
hotspot
explore
-
AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B
2025-09-30 21:47 -
Bispecific antibodies are next new thing in cancer immunotherapy
2025-09-30 20:55 -
Sea level rise could wash away turtle breeding grounds around the world, researchers say
2025-09-30 20:07 -
FDA needs staff influx to meet gene therapy needs, Marks says
2025-09-30 19:50 -
Biogen nominates mother of director’s child to replace him on board
2025-09-30 19:41 -
Timeline: Key moments in fight for gay rights
2025-09-30 19:38